Welcome to our dedicated page for MDVA news (Ticker: MDVA), a resource for investors and traders seeking the latest updates and insights on MDVA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MDVA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MDVA's position in the market.
Modiv Inc. has priced an underwritten public offering of 40,000 shares of its Class C Common Stock at $25.00 per share, facilitating the stock's upcoming trading on the NYSE under the ticker 'MDV.' Expected trading begins on February 11, 2022, with closing anticipated on February 15, 2022. After the offering, the total shares of Class C Common Stock will number 7,561,211. The share conversion from Class S to Class C will also occur upon listing, and the Preferred Stock ticker will change from 'MDVA' to 'MDV.PRA.'
